Foghorn Therapeutics(US:FHTX) ZACKS·2025-02-27 16:06Core Viewpoint - The market anticipates Foghorn Therapeutics Inc. (FHTX) to report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended December 2024 [1] Financial Expectations - The consensus EPS estimate for Foghorn Therapeutics is a loss of $0.29 per share, reflecting a year-over-year improvement of +49.1% [3] - Expected revenues for the quarter are $11.72 million, which represents a significant increase of 103.1% compared to the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analysts' assessments [4] - The Most Accurate Estimate for Foghorn Therapeutics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -29.07%, suggesting a bearish outlook from analysts [10] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with a focus on positive readings [7] - A positive Earnings ESP combined with a strong Zacks Rank (1-3) has historically led to a positive surprise nearly 70% of the time [8] Historical Performance - In the last reported quarter, Foghorn Therapeutics was expected to post a loss of $0.42 per share but delivered a loss of $0.31, resulting in a positive surprise of +26.19% [12] - Over the past four quarters, the company has beaten consensus EPS estimates three times [13] Industry Comparison - Another company in the same industry, Wave Life Sciences, is expected to report a loss of $0.17 per share, indicating a year-over-year change of -13.3%, with revenues projected at $29.14 million, up 0.3% from the previous year [17] - Wave Life Sciences has an Earnings ESP of 40.68%, suggesting a higher likelihood of beating the consensus EPS estimate, despite only surpassing EPS estimates once in the last four quarters [18]